Physician profile
Sara Levy
NPI 1609380302
$4,670.78
in general payments reported to CMS, 2019-2025
27 companies · $2,466 in 2025
The $2,466 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $205 · 2024: $2,000 · 2025: $2,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,429 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.81 |
| Education | $241.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $767.80 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $663.00 | 2023-2025 | Tremfya |
| Abbvie INC. | $535.59 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $437.48 | 2024-2025 | Sotyktu |
| Ucb, INC. | $289.30 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $275.45 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $245.66 | 2024-2025 | |
| Galderma Laboratories, L.P. | $229.69 | 2024-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $222.50 | 2024 | Vtama |
| Genzyme Corporation | $181.19 | 2024-2025 | |
| Amgen INC. | $141.61 | 2023-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Almirall LLC | $85.86 | 2024-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $84.94 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $75.15 | 2024-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $51.03 | 2024 | Sotyktu |
| Pfizer INC. | $47.79 | 2024-2025 | |
| Organon LLC | $41.08 | 2025 | |
| Leo Pharma INC. | $36.86 | 2025 | Adbry |
| Journey Medical Corporation | $33.48 | 2024 | |
| Insulet Corporation | $22.89 | 2025 | Omnipod |
| Regeneron Healthcare Solutions, INC. | $20.00 | 2025 | Libtayo |
| Botanix Sb INC | $18.13 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $17.33 | 2025 | Daxxify |
| Lnhc, INC | $17.28 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.77 | 2024 | Arazlo, Cabtreo |
| Kyowa Kirin, INC. | $14.93 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.